Oxygenta Pharmaceutical Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing continued operational challenges despite revenue growth. The pharmaceutical manufacturer reported a net loss of ₹484.30 lakhs for Q3 FY26, representing a 23.28% increase in losses compared to ₹392.82 lakhs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed mixed results, with revenue growth offset by increased operational losses. Despite achieving higher sales, the company faced significant cost pressures that impacted profitability.

Cost Structure Analysis

The company's expense structure revealed several pressure points during the quarter. Cost of materials consumed stood at ₹3,117.03 lakhs in Q3 FY26 compared to ₹3,760.65 lakhs in Q3 FY25. However, other operational expenses increased significantly, including finance costs which rose to ₹139.08 lakhs from ₹38.83 lakhs in the previous year quarter.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Oxygenta Pharmaceutical reported revenue from operations of ₹6,336.79 lakhs compared to ₹5,983.21 lakhs in the corresponding period of the previous year. The net loss for the nine-month period widened to ₹1,591.42 lakhs from ₹814.54 lakhs in the previous year.

Corporate Governance Updates

The Board of Directors, during their meeting held on February 4, 2026, approved the re-constitution of the Internal Complaints Committee under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013. The committee comprises eight members including Mrs. G. Durga Bhavani as Presiding Officer and Ms. D. Rajeswari as External Member.

Operational Challenges

The company acknowledged ongoing challenges in identifying MSME creditors and implementing bill-to-bill adjustment processes. Management stated they are actively working to complete supplier identification through self-declaration forms and are committed to achieving full compliance and transparency in reporting. The company operates in a single segment of pharmaceutical product manufacturing, with paid-up equity share capital of ₹3,698.35 lakhs.

Oxygenta Pharmaceutical Limited has seen an increase in Virupaksha Organics Limited's stake through additional equity share acquisitions in the open market. Virupaksha Organics acquired 1,95,885 equity shares of Oxygenta Pharmaceutical Limited, raising its shareholding from 55.37% to 55.90%.

Transaction Details

The share acquisition was executed through open market purchases, with Virupaksha Organics acting as the promoter of Oxygenta Pharmaceutical Limited. The transaction details are summarized below:

Shareholding Pattern Changes

The acquisition has resulted in a marginal increase in Virupaksha Organics' stake in Oxygenta Pharmaceutical. The shareholding pattern before and after the transaction shows the following changes:

Market Implications

This acquisition reinforces Virupaksha Organics' commitment to maintaining its controlling stake in Oxygenta Pharmaceutical Limited. The transaction was conducted through regular market channels, indicating standard investment activity rather than any strategic restructuring. The modest increase in shareholding percentage suggests routine portfolio management by the promoter entity.